- Home
- PVL vs EGRX Comparison
PVL vs EGRX Comparison
Compare PVL & EGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVL
- EGRX
- Stock Information
- Founded
- PVL 2011
- EGRX 2007
- Country
- PVL United States
- EGRX United States
- Employees
- PVL N/A
- EGRX N/A
- Industry
- PVL Oil & Gas Production
- EGRX Biotechnology: Pharmaceutical Preparations
- Sector
- PVL Energy
- EGRX Health Care
- Exchange
- PVL Nasdaq
- EGRX Nasdaq
- Market Cap
- PVL 52.5M
- EGRX 50.7M
- IPO Year
- PVL N/A
- EGRX 2014
- Fundamental
- Price
- PVL $1.62
- EGRX $1.99
- Analyst Decision
- PVL
- EGRX
- Analyst Count
- PVL 0
- EGRX 0
- Target Price
- PVL N/A
- EGRX N/A
- AVG Volume (30 Days)
- PVL 82.7K
- EGRX 321.6K
- Earning Date
- PVL 01-01-0001
- EGRX 11-12-2024
- Dividend Yield
- PVL 4.06%
- EGRX N/A
- EPS Growth
- PVL N/A
- EGRX N/A
- EPS
- PVL 0.23
- EGRX 0.91
- Revenue
- PVL $3,338,026.00
- EGRX $257,551,000.00
- Revenue This Year
- PVL N/A
- EGRX N/A
- Revenue Next Year
- PVL N/A
- EGRX N/A
- P/E Ratio
- PVL $7.04
- EGRX $2.35
- Revenue Growth
- PVL N/A
- EGRX N/A
- 52 Week Low
- PVL $1.03
- EGRX $1.80
- 52 Week High
- PVL $2.40
- EGRX $14.78
- Technical
- Relative Strength Index (RSI)
- PVL 48.10
- EGRX 19.60
- Support Level
- PVL $1.53
- EGRX $1.80
- Resistance Level
- PVL $1.64
- EGRX $4.11
- Average True Range (ATR)
- PVL 0.06
- EGRX 0.40
- MACD
- PVL -0.00
- EGRX -0.19
- Stochastic Oscillator
- PVL 42.86
- EGRX 6.86
About PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production the sale of oil and natural gas production from primarily non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About EGRX Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.